Waters Corporation
WATHealthcareNASDAQDiagnostics & Research · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Waters Corporation focuses on Diagnostics & Research services and products. Waters Corporation provides analytical workflow solutions in Asia, the Americas, and Europe. The company carries a $44.54B market cap, placing it firmly in the large-cap category. The company operates through two segments, Waters and TA.
Market Cap
$44.54B
Beta
1.15
P/E (TTM)
114.85
P/E (Fwd)
27.41
EPS (TTM)
$3.95
EPS (Fwd)
$16.55
ROE
1.9%
ROA
3.6%
Cash
$539.0M
Total Debt
$5.48B
Free CF
-$142.1M
52W Change
29.0%
Annual Financials
Cash vs Debt
Where WAT stands vs its 150-day and 200-day moving averages
As of the October 12, 2026 close, WAT finished 18.61% above its 150-day moving average ($365.72) and 18.86% above its 200-day moving average ($364.95). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is WAT overbought or oversold?
At the October 12, 2026 close, WAT's RSI(14) was 56.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The company holds $539.0M in cash, though total debt stands at $5.48B. This level of leverage is common in the industry but worth monitoring as interest rate conditions evolve. The company is burning cash, with free cash flow at -$142.1M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at 1.9%, which is modest for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. ROA of 3.6% is on the lower side, which is common in asset-heavy industries. Revenue has been relatively flat, moving from $2.97B (2022) to $3.17B (2025).
Waters Corporation carries a heavier debt load relative to its cash position, which introduces financial risk that investors should weigh. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. At over 50x earnings, WAT carries valuation risk — any slowdown in growth expectations could lead to meaningful price adjustments. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing WAT.